Change over period: —
NSE · MANGALAM
MAN DRUGORG
-54.6% from the 52-week high · +19.4% above the low
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra and currently employs 523 full-time employees. The company went IPO on 2005-05-26. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. The company also focuses on specialty chemicals. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
The short version. MAN DRUGORG reported revenue of ₹79 crore for Sep 2026, up 58.0% from a year earlier. Net profit was ₹-7 crore. Return on equity was -43.1% in Mar 2026. Promoter holding was 35.65% in Sep 2026, down 14.65 points over 8 quarters.
1 · The price
How has the stock traded?
MAN DRUGORG trades 54.6% below its 52-week high and 19.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹79 cr.
5.7 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 79 | 57 | 67 | 58 | 50 | 57 | 73 | 89 |
| Net profit | -7 | -8 | -13 | -10 | -7 | -14 | 0 | 1 |
| Net margin % | -9.1 | -13.4 | -19.9 | -16.8 | -14.8 | -24.1 | 0.1 | 1.5 |
| EPS (₹) | -4.55 | -4.83 | -8.48 | -6.21 | -4.64 | -8.72 | 0.04 | 0.81 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 232 | 318 | 369 |
| Net profit | -44 | 7 | -9 |
| Net margin % | -19.1 | 2.1 | -2.5 |
| EPS (₹) | -28.05 | 4.25 | -5.73 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -43.1% in Mar 2026; debt to equity is 1.02.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -43.1 | 4.5 | -6.7 | — |
| Return on capital % | -27.3 | 11.3 | 1.7 | — |
| EBITDA margin % | -6.1 | 11.4 | 4.8 | — |
| Net margin % | -19.1 | 2.1 | -2.5 | — |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 14.65 pts over 8 quarters.
Unchanged over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.3 | 50.3 | 50.3 | 50.3 | 35.64 | 35.65 | 35.65 | 35.65 | -14.65 |
| FII | 0.11 | 0.47 | 0.53 | 0.11 | 0.13 | 0.32 | 0.11 | 0.11 | 0.0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 49.58 | 49.23 | 49.16 | 49.58 | 64.22 | 64.02 | 64.24 | 64.24 | +14.66 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MAN DRUGORG are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about MAN DRUGORG
What is the MAN DRUGORG share price?
MAN DRUGORG (MANGALAM) last closed at ₹28.42, up 0.11% on the day. Its 52-week range is ₹23.78 to ₹62.58.
What is the market cap of MAN DRUGORG?
MAN DRUGORG has a market capitalisation of about ₹45 crore.
How are MAN DRUGORG's latest results?
MAN DRUGORG reported revenue of ₹79 crore for Sep 2026, up 58.0% from a year earlier. Net profit was ₹-7 crore. Return on equity was -43.1% in Mar 2026. Promoter holding was 35.65% in Sep 2026, down 14.65 points over 8 quarters.
Who owns MAN DRUGORG?
As of Sep 2026, shareholding was: Promoter 35.65%, FII 0.11%, Public 64.24%.
How many mutual funds hold MAN DRUGORG?
0 mutual fund schemes held MAN DRUGORG in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 21 Dec 2017 · Interim Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.